IMUX

Immunic (IMUX)

About Immunic (IMUX)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

Details

Daily high

$15.35

Daily low

$14.20

Price at open

$14.25

52 Week High

$15.77

52 Week Low

$5.06

Market cap

193.4M

Dividend yield

0.00%

Volume

302,500

Avg. volume

248,000

P/E ratio

-2.35

Immunic News